Option chain shows key data for Vivos's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Vivos.

Vivos (OTC:RDGL) Stock, Option Chain

Vivos Inc is a radiation oncology medical device company. It is engaged in the development of RadioGel which is a brachytherapy device comprising highly insoluble particles delivered by needle injection using a water-polymer composite for high-dose treatment of non-resectable solid tumors. IsoPet is another product of the company used for the treatment of solid tumors in animals. The company derives revenue through sales of its products.

Screenshot 2025-04-28 at 7.50.33 PM

Biotech

General

RDGL

Vivos Inc Has Reported Positive Results With Its First Ever Human Trial

Screenshot 2025-03-27 at 9.02.22 PM

News

Vivos Inc.&#39;s Says Its Innovative Cancer Treatment Will Offer New Therapeutic Solution Using Proprietary Precision Radionuclide Therapy™

Penny,Stock,Investments,Taking,Off,Concept

Long Ideas

Penny Stocks

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

PAPL

VANI

Pineapple Financial And 1 Other Stock Under $1 Insiders Are Buying

Vivos Inc

Press Releases

Vivos Inc. Submits the Application to the FDA for Authority to Initiate Human Clinical Trials

Vivos One Step Closer To Transforming Cancer Treatment With FDA Application To Start Human Trials For Pioneering Injectable Brachytherapy Device

Vivos Inc. Provides IDE Submission Status Update – Conversion to Pre-Sub Filing Accepted by the FDA

Vivos Inc. Extended its IsoPet® Precision Radionuclide TherapyTM to Exotics

Vivos Inc. Certifies New Clinic for IsoPet® Precision Radionuclide TherapyTM

Vivos Inc. Announces Launch of Groundbreaking RadioGel® Precision Radionuclide Therapy™ Human Clinical Trial

Vivos Inc.'s IsoPet® Division Achieves Exceptional Growth in 2024, Expanding Certified Veterinary Clinics Nationwide

Vivos Inc. Reports Encouraging Human Clinical Trial Results and Announces Expansion Plans

Vivos Inc. Reports Continued Progress in India Human Clinical Trial for RadioGel® Precision Radionuclide Therapy™

Vivos Inc. Achieves Record Growth in IsoPet® Animal Cancer Treatments in Q1 2025

Vivos

Screenshot 2024-07-01 at 8.57.06 AM

Comments

Vivos

Vivos (RDGL) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell